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The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious
insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy
(DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including
microglia, perivascular macrophages, and a small population of dendritic cells) and the complement
system. Under normal aging conditions, retinal innate immune cells and the complement system un-
dergo a low-grade activation (parainﬂammation) which is important for retinal homeostasis. In disease
states such as AMD and DR, the parainﬂammatory response is dysregulated and develops into detri-
mental chronic inﬂammation. Complement activation in the retina is an important part of chronic in-
ﬂammation and may contribute to retinal pathology in these disease states. Here, we review the evi-
dence that supports the role of uncontrolled or dysregulated complement activation in various retinal
degenerative and angiogenic conditions. We also discuss current strategies that are used to develop
complement-based therapies for retinal diseases such as AMD. The potential beneﬁts of complement
inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to
better understand the mechanisms of complement-mediated retinal damage in these disease states.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. The retina – an immune privileged tissue
The retina is essential for perception of vision. Light enters the
eye through the cornea and iris and passes through the vitreous
body to project onto the retina where the light signal is converted
into electric impulses (Fig. 1A). The visual cycle occurs at the in-
terface between the retina and retinal pigment epithelium (RPE),
leading to the depolarization of photoreceptors (the rods and the
cones). The electrical impulses converge via bipolar cells and
ganglion cells onto the optic nerve, and then into the visual cortex
(Fig. 1B). The inner retinal cells obtain nutrients and oxygen from
the retinal circulation (Fig. 1C), whereas the outer retinal layers
(which consists of the outer nuclear layer (ONL), photoreceptor
inner segment (IS), and outer segment (OS)) are avascularized and
nutrients and oxygen are supplied by the choroidal circulation
(Fig. 1B). To ensure good visual function, this complex and so-
phisticated structure must be maintained throughout life, and
even a minor perturbation may cause devastating visual
impairment.
The eye has special mechanisms to protect the retina fromr B.V. This is an open access article
te of Experimental Medicine,
T9 7BL, UK.
.chen@qub.ac.uk (M. Chen).exogenous and endogenous insults, which not only reduces the
risk of infection, but also prevents inappropriate immune re-
sponses, thereby reducing the risk of inﬂammation–mediated
retinal damage. Firstly, the retina is protected by physical barriers.
The blood retina barrier (BRB) is formed by tight junctions be-
tween vascular endothelial cells (inner BRB, iBRB) and RPE cells
(outer BRB, oBRB), and ensures that pathogens, circulating cells
and molecules do not freely pass into the retinal parenchyma. The
BRB also sequesters retinal antigens within the intraocular com-
partment avoiding T cell activation, a phenomenon called im-
munological ignorance (Avichezer et al., 2003; Forrester et al.,
2008; Forrester et al., 2010; Forrester and Xu, 2012). Secondly, the
retina has no lymphatic system. Therefore, when the retina suffers
from any insult, the endogenous alarmins are unlikely to be de-
tected by circulating or choroidal antigen presenting cells (APCs) if
the BRB is intact. Thirdly, the retina has a sophisticated immune
regulatory system orchestrated by retinal cells, including various
neurons and RPE cells (Streilein, 1999; Streilein et al., 2002;
Wenkel and Streilein, 2000). These retinal cells express immune
modulators that can suppress immune cell activation. Examples of
the immune modulatory mechanisms include (but are not limited
to) the CD200-CD200R (Dick et al., 2003) and CX3CL1-CX3CR1
(Combadiere et al., 2007) pathway, thrombospondin-1, TGF-β,
CTLA4, CTLA2, and various complement inhibitors (Horie et al.,
2010; Kawazoe et al., 2012; Mochizuki et al., 2013; Sugita et al.,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Retinal neuronal and vascular structure and retinal disease. A, diagram of a human eye. Light passes through the pupil and is focused by the lens onto the macula of
the retinal layer at the back of the eye. B, the retina consists of three layers of neurons, photoreceptor, bipolar, and ganglion cells. The RPE monolayer together with Bruch's
membrane (BM) form the outer blood retinal barrier that separates the neuroretina from the choroid. Choroidal circulation provides oxygen and nutrients to the outer retina.
C, the retina has an interconnected network of three vascular layers located in the ganglion cell/nerve ﬁbre layer, inner plexiform layer (IPL), and outer plexiform layer (OPL).
D, retinal tissue and cells that are affected under different disease conditions.
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inﬁltrating immune cells through Fas ligand (FasL) and Tumor
Necrosis Factor-related apoptosis-inducing ligand (TRAIL) path-
ways also exist in the retina (Ferguson and Grifﬁth, 1997; Ferguson
and Grifﬁth, 2007; Kazama et al., 2008). Furthermore, ocular ﬂuids
contain immunoinhibitory molecules such as TGF-β2 and neuro-
peptides, including α-melanocyte-stimulating hormone and va-
soactive intestinal peptide (Taylor, 1996; Taylor and Lee, 2010). The
retina, therefore, represents an immune privileged tissue (For-
rester et al., 2008; Gregerson, 1998; Streilein et al., 2002).
Despite being an immune privileged tissue, both retinal neu-
rons and the vascular system may degenerate in conditions such
as diabetic retinopathy (DR), age-related macular degeneration
(AMD), uveoretinitis and glaucoma (Fig. 1D). Although the initial
triggers of different diseases may differ, the retinal immune re-
sponse following the initial insult shares many common pathways.
Such inﬂammatory response secondary to retinal damage critically
contributes to further neuronal and vascular degeneration in the
aforementioned sight-threatening diseases. Here, we review the
current knowledge on how the retinal innate immune system
responds to insults with a strong focus on the complement system,
and further discuss how the knowledge can be applied to devel-
oping complement based therapy.2. Tissue insults, inﬂammation and disease – the concept
The central role of the immune system is to protect the host
from exogenous and endogenous insults. When a tissue suffers
from non-infectious noxious insults, a cell-autonomous response
is initiated for stressor elimination or stress adaptation. This may
include the upregulation of the autophagy pathway, the initiation
of DNA repair, and the induction of chaperones to help to prevent
protein misfolding (the adaptation response). The adaptation re-
sponse is especially important for aging and diabetes. In addition,
a non-cell-autonomous response may also be initiated whereinstressed cells release cytokines, chemokines and growth factors
that affect neighbouring cells within the tissue, promoting tissue
level adaptation. In the literature, this tissue autonomous response
(cell-autonomous or non-cell-autonomous) is often called “in-
ﬂammation” when inﬂammatory cytokines and chemokines are
released by stressed cells.
Although many cells can detect tissue stress, this function is
performed most efﬁciently by specialized sensory cells, such as
tissue resident macrophages. Thus, pathogens and generic stres-
sors such as hypoxia and oxidized lipids/proteins are primarily
delegated to macrophages. Tissue macrophages may orchestrate
tissue level defence and adaptations by releasing inﬂammatory
mediators, including complement components. If the level of in-
sult exceeds the repair capacity of tissue macrophages, they may
recruit circulating immune cells to sites of damage. A low-level of
tissue insult may initiate a protective para-inﬂammation (Chova-
tiya and Medzhitov, 2014; Medzhitov, 2008). When the stress
persists for a sustained period of time, the affected tissue may
mal-adapt leading to loss of function. In addition, the immune
system may respond inappropriately to tissue stress due to genetic
and epigenetic modiﬁcations resulting in dysregulated para-in-
ﬂammation (chronic inﬂammation). Tissue pathology (disease)
may occur as a result of tissue mal-adaptation or immune
dysregulation.3. Retinal innate immune defence and disease
As an immune privileged tissue, circulating immune cells are
not able to enter the retina to deal with endogenous insults under
normal physiological conditions. However, the retina has a unique
immune defence system consisting of innate immune cells and the
complement system. The retina contains at least three types of
innate immune cells: microglia, perivascular macrophages, and
dendritic cells (DCs) (Forrester et al., 2010; Xu et al., 2009). Al-
though both perivascular macrophages and microglia express
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receptor) and CD45, whereas microglia are CD14-CD45low (Dick
et al., 1995; Fischer and Reichmann, 2001; Tavazzi et al., 2014).
Perivascular macrophages safeguard retinal vessels and are criti-
cally involved in retinal vascular homeostasis. Whether or not the
retina has DCs has been a debate for decades. Early work by Zhang
and colleagues reported a small population of MHC-IIþ cells in rat
retina (Zhang et al., 1997). Using ﬂow cytometry analysis, Gre-
gerson and Yang detected a small population of CD11cþ DEC205þ
DCs in normal mouse retina (Gregerson and Yang, 2003). They
further conﬁrmed the existence of retinal CD11c cells using CD11c-
DTR transgenic mice (Lehmann et al., 2010), although a later study
suggested that rd8 mutation in the Crb1 gene may contribute to
the abnormal number of CD11cþ cells in the retina in CD11c-eYFP
transgenic mice (Chen et al., 2013b). Previously, we identiﬁed a
small population of MHC-IIþ33D1þ DCs in mouse retina which
are located around the optic disc and the peripheral retinal margin
area (Xu et al., 2007). The function of these cells is unclear, but
their strategic location suggests they may be “gatekeepers” of the
retina. In experimental autoimmune uveoretinitis (EAU), these DCs
are activated prior to overt retinal inﬂammation and their activa-
tion is associated with early cell inﬁltration around the optic disc
and peripheral retinal margin (Xu et al., 2007). These retinal DCs
are activated in experimental models of optic nerve degeneration
and they can phagocytose dead ganglion cells (Heuss et al., 2014;
Lehmann et al., 2010). Ganglion cell degeneration/optic disc cup-
ping is the key biological change in glaucoma. The MHC-IIþ33D1þ
juxtapapillary DCs may be critically involved in the pathogenesis
of glaucoma. Microglia form an important part of retinal immune
defence. They are located in the inner layers of the retina, and are
distributed into three layers: the ganglion layer (GL), the inner
plexiform layer (IPL) and outer plexiform layer (OPL) (Chen and
Xu, 2015). Under normal physiological conditions, microglia are in
a resting state with a small cell body and long, thin dendrites. They
are activated in disease states, such as in AMD, DR, and uveor-
etinitis. Microglial activation may contribute to further retinalFig. 2. Complement activation and immune regulation. The complement system can be
the alternative pathway (AP); all leads to the cleavage of C3 and C5 and the formation of
pathways and C3bBb of the AP. C5 is cleavaged by C5 convertases, which include C4b
complement system generates C4a, C3a, C3b and C5a fragments that are actively inv
promoting phagocytosis. C3a and C5a are anaphylatoxins that have multiple immune re
can also promote inﬂammation.damage and disease progression. The role of retinal microglia in
retinal health and disease has been reviewed extensively else-
where (Karlstetter et al., 2010; Karlstetter et al., 2015; Langmann,
2007; Li et al., 2015).
In addition to retinal innate immune cells, compelling evidence
suggests that the complement system also plays a critical role in
protecting the retina from exogenous and endogenous insults.
Dysregulated complement activation may contribute to retinal
disease and targeting the complement system may offer oppor-
tunities for therapy.4. The complement system
The complement system is an important part of the innate
immune system. It complements antibodies and phagocytes to
clear pathogens from the host. The complement system consists of
over 30 small proteins and protein fragments and the majority of
them are thought to be produced in the liver as inactive precursors
and released into the circulation for tissue distribution. The com-
plement system can be activated by at least three pathways: the
classical pathway (CP), the mannose-binding lectin (MBL) path-
way, and the alternative pathway (AP) (Fig. 2). There are two cri-
tical steps for the full activation of the complement pathways: C3
cleavage and C5 cleavage. A fully activated complement system
results in the formation of the membrane attack complex (MAC, or
C5b-C9) (Fig. 2) that can kill pathogens and cells. It is important to
note that under physiological conditions, the complement system
is constantly activated at a low-level (through the AP) and the
harmful effects are prevented by various endogenous soluble and
membrane-bound inhibitory molecules. For example, the MAC can
be turned into harmless soluble SC5b-9 complex by S-protein/Vi-
tronectin under physiological conditions (Su, 1996). In addition,
recent evidence suggests that sub-lytic MAC may have immune
modulatory roles, e.g., inducing IL-6, IL-8, CCL2 and VEGF pro-
duction (Lakkaraju et al., 2014; Lueck et al., 2011). The keyactivated by the classical pathway (CP), mannose-binding lectin (MBL) pathway and
C5b-C9. C3 is cleavaged by C3 convertases, which include C4bC2b of the CP and MBL
C2bC3b of the CP and MBL pathways and C3bBbC3b of the AP. Activation of the
olved in immune responses. C3b opsonizes foreign antigens and apoptotic cells,
gulatory roles. The C5b-C9 may directly kill pathogens or cells. The sub-lytic C5b-9
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i.e. C3 and C5 convertase, are formed. The convertases of C3 and C5
of the CP and the lectin pathway comprise the complement
components C4bC2b and C4bC2bC3b respectively, while in the AP
they are composed of C3bBb (C3 convertase) and C3bBbC3b (C5
convertase) (Fig. 2) (Zipfel and Skerka, 2009). In addition, com-
plement can also be activated by a pathway that acts in-
dependently of C3 to bypass the C3 convertase and is mediated by
direct thrombin action on the C5 convertase (Huber-Lang et al.,
2006).
Traditionally the complement system is thought to be im-
portant for the elimination of invasive microbes (through cell lysis
by MAC) and removal of waste (through opsonisation and pro-
moting phagocytosis by C3b). Compelling evidence suggests that
complement also plays critical roles in regulating inﬂammatory
and immunological processes. Complement fragments C3a and
C5a are anaphylatoxins and can induce vasodilation, increase the
permeability of small blood vessels and induce contraction of
smooth muscles (Fig. 2). C3a and C5a are chemotactic to neu-
trophils, mast cells, and lymphocytes. They can trigger oxidative
burst in macrophages and eosinophils, and induce the release of
histamine from basophils and mast cells (Fig. 2). C3a and C5a can
enhance antigen presentation by DCs and promote Th1 cell dif-
ferentiation (Sacks, 2010). In addition to their proinﬂammatory
properties, C3a and C5a also participate in tissue regeneration and
ﬁbrosis (Hillebrandt et al., 2005; Strey et al., 2003).
C3a and C5a exert most of their biological activities through
ligation of three cognate receptors: the C3a receptor (C3aR), the
C5a receptor (C5aR), and the chemoattractant receptor-like protein
C5L2. These receptors are widely expressed by immune cells and
non-immune cells. Therefore, a fully activated complement path-
way can modulate the immune response at multiple levels.
Recent evidence suggests that C3a can also be generated in-
dependent of complement activation through intracellular clea-
vage of C3 by cathepsin L (Liszewski et al., 2013). This local gen-
eration of anaphylatoxins is important for their pleiotropic biolo-
gic effects beyond inﬂammation.5. Complement regulation in the retina
Compelling evidence suggests that a complement regulatory
system exists in the retina-RPE/choroid. The mRNA of complement
components including C1qb, C1r, C2, C3, C4, complement factor B
(CFB), and factor H (CFH) have been detected in the retina and
RPE/choroid of human (Anderson et al., 2010) and mouse eyes (Luo
et al., 2011). Retinal microglia and RPE cells appear to be the major
cellular sources of local complement expression (Luo et al., 2011).
The retina/RPE/choroid also expresses complement regulatory
proteins. For example, CD46 was detected at the basal surface of
RPE cells (Fett et al., 2012; Vogt et al., 2006), CD55 in ganglion and
photoreceptors, CD59 in retinal nerve ﬁbers (Vogt et al., 2006), and
CFH in RPE (Chen et al., 2007) and choriocapillaris (Fett et al.,
2012). The complement receptor CR1 and C3aR were detected in
ganglion cells (Fett et al., 2012), whereas C5aR was detected in the
inner plexiform layer (Vogt et al., 2006). In vitro studies have
shown that RPE cells (Fukuoka and Medof, 2001), astrocytes
(Gasque et al., 1995), and Muller cells (Cheng et al., 2013) all ex-
press C5aR.
An age-dependent upregulation of complement genes was
observed in the retina (Chen et al., 2010a) and RPE/choroid (Chen
et al., 2008a, 2008b) in mice. A recent study has reported an age-
related accumulation of MAC in the choriocapillaris of healthy
donor eyes (Chirco et al., 2015, Mullins et al., 2014). We have
previously shown that expression of complement C3, C4, and CFB
in mouse retina can be affected by cataract surgery (Xu et al., 2011)and irradiation (Chen et al., 2012). In vitro studies have further
shown that complement expression by retinal cells is regulated by
inﬂammatory cytokines and chemokines. For example, the ex-
pression of complement and regulatory genes by RPE cells can be
regulated by cytokines such as TNF-α, IFN-γ, IL-27 (Amadi-Obi
et al., 2012; Chen et al., 2007; Chen et al., 2008b; Lau et al., 2011)
or the supernatants of macrophages (Luo et al., 2013). These re-
sults suggest that the retinal complement system is actively re-
sponding to ocular microenvironmental stimulations.
Although the physiological role of the complement system in
retinal health and disease is not fully understood, the fact that the
retina only express selected components of complement proteins
and regulatory molecules suggests that the complement system
cannot fully be activated if the BRB is intact. It also suggests that
the retina has the capacity to control local complement activation
when the BRB is broken down. This may have important im-
plications in developing complement based therapy for retinal
diseases, i.e., controlling complement activation locally in the re-
tina rather than systemically may be a more effective approach.6. Complement activation and retinal diseases
6.1. Complement activation in Uveoretinitis
Uveoretinitis is an inﬂammatory condition that involves the
uveal tract and the retina of the eye. The disease can cause de-
vastating vision loss if left untreated. Current treatment of
uveoretinitis is through local or systemic administration of im-
munosuppressants, which is often associated with severe adverse
effects such as cataract and glaucoma and there is an urgent need
to develop new effective and safe therapies.
Complement activation is known to be involved in the patho-
genesis of uveoretinitis. The aqueous humor of uveitis patients
contains high levels of C3a, C3c and CFB (Mondino et al., 1984).
Polymorphisms in complement genes, including CFH, SERPING
(Thompson et al., 2013; Yang et al., 2011; Yang et al., 2013), and C5
(Xu et al., 2015) increase the risk of uveitis. EAU is an established
model of human posterior uveoretinitis (Caspi et al., 1990; Caspi
et al., 1994; Forrester et al., 1992). The disease represents a T cell
driven autoimmune response to retinal antigens (Caspi et al., 1990;
Liversidge and Forrester, 1988) in which both Th1 and Th17 cells
are involved (Amadi-Obi et al., 2007; Luger et al., 2008). Mice
deﬁcient in complement C3 are less susceptible to EAU (Read et al.,
2006), whereas mice deﬁcient in the decay-accelerating factor
(DAF) develop greater EAU than their wild-type controls (An et al.,
2009). Furthermore, EAU can be suppressed by introducing the
soluble complement inhibitor (sCrry) (Read et al., 2006), re-
combinant DAF (An et al., 2009), or complement C5 monoclonal
antibody (Copland et al., 2010). We have shown that CFB mRNA
was signiﬁcantly increased in EAU retina and that blocking the AP
complement activation using fusion protein CRIg-Fc could sup-
press retinal inﬂammation in the mouse model of EAU (Chen et al.,
2010b).
The complement system may contribute to retinal pathology in
uveoretinitis at multiple levels. In addition to MAC-mediated cell
death, C3a and C5a may modulate T cell activation. C5a/C5aR
pathway is known to be involved in Th1 cell activation and dele-
tion this pathway leads to Th17 and T regulatory (Treg) cell dif-
ferentiation (Weaver et al., 2010; Xu et al., 2010). Mice deﬁcient in
C3aR/C5aR are resistant to EAU induction (Zhang et al., 2015).
6.2. Complement activation in AMD
AMD is the progressive degeneration of the macula (central
part of the retina) in people aged over 55 years. AMD is the leading
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counting for 8.7% of all blindness worldwide and is predicted to
affect 196 million people by 2020 (Wong et al., 2014).
The early stages of the disease is characterised by large drusen
(463 mm) and hypo- and hyper-pigmentation of RPE in the ma-
cula (Ferris et al., 2013). The disease may progress into two late
stages, dry- and wet-AMD. Wet AMD (also called neovascular
AMD, nAMD) is a condition in which abnormal blood vessels grow
into the subretinal space of the macula causing visual damage.
Wet AMD accounts for two thirds of all late stage AMD. The dis-
ease is treated by intravitreal injection of VEGF inhibitors (e.g.,
Avastin, Lucentiss, Eyelea) (Heier et al., 2006; Holz et al., 2014;
Kodjikian et al., 2014). Dry AMD (also called geographic atrophic,
GA) is caused by RPE cell death and photoreceptor degeneration,
for which there is currently no treatment.
The role of the complement system in the pathogenesis of AMD
has been studied extensively over the past decade and a few ex-
cellent review articles have detailed the advancements in this ﬁeld
(Bora et al., 2015; McHarg et al., 2015; Warwick et al., 2014). Here
we summarize the key evidence supporting the role of the com-
plement system in the pathogenesis of AMD. Firstly, various
complement components, including C3, C5b-9, CFB, and CFH have
been detected in drusen as well as in AMD lesions (Anderson et al.,
2002; Anderson et al., 2010). In addition, increased plasma levels
of C3a, C3d, Bb, and C5a have been observed in AMD patients
(Lechner et al., 2016; Reynolds et al., 2009; Scholl et al., 2008).
These results suggest increased local and systemic complement
activation in AMD. Secondly, polymorphisms in a number of
complement genes (CFH, CFB, C2, SERPING1, and C3) increase the
risk of AMD (Cipriani et al., 2012; Edwards, 2008; Katta et al.,
2009). The genetic evidence suggests that the complement system,
and in particular the alternative pathway may be dysregulated in
AMD patients. Last but not least, experimental studies have shown
that inhibition of complement activation via either systemic or
local routes can suppress laser-induced CNV. Inhibition of C3a, C5a
(Nozaki et al., 2006), CFB, and MAC (Lipo et al., 2013), or admin-
istration of the complement regulatory molecules CD59 (Bora
et al., 2010) and CFH (Kim et al., 2013) can suppress CNV devel-
opment in animal models.
6.3. Complement activation in DR
DR is a progressive degeneration of retinal vasculature and
neurons as a result of diabetes. The longer a person has diabetes,
the higher the chance he/she might develop DR. After 20 years of
the disease, nearly all patients with type 1 diabetes will have at
least some DR. For type 2 diabetes, around 80% who are insulin-
dependent and 50% who are non-insulin-dependent will have DR
after 20 years (Romero-Aroca et al., 2010). DR is the leading cause
of blindness among people of working age in Western countries
(Aiello et al., 1998).
In the early stages, patients may present with microaneurysms,
hard exudates, haemorrhages, and cotton-wool spots in the fun-
dus. The diseased vessels may leak ﬂuid from the circulation into
the macula (i.e. diabetic macular oedema) leading to severe vision
loss. As the disease progresses, new blood vessels may grow
(proliferative DR) as a result of severe isehemia. The new blood
vessels are fragile and can cause severe haemorrhage and ulti-
mately destroy the retina.
In addition to vascular damage, retinal neural cells may also be
affected even at the early stages of the diabetes. There is growing
evidence to suggest that retinal neuron damage, in particular the
reactive oxygen species (ROS) released by stressed photoreceptors
is an early event in DR pathogenesis (Du et al., 2013; Simo et al.,
2012).
The underlying mechanisms leading to retinal vasculopathyand neuropathy in diabetes are not fully understood, although
oxidative stress and inﬂammation are known to be important
detrimental factors. The role of inﬂammation and various in-
ﬂammatory mediators (such as cyclooxygenase (COX), TNF-α, IL-
1β, and HMGB-1), AGEs, and S100B in different stages of DR
pathologies has been reviewed extensively elsewhere (Chen et al.,
2013a, 2013b; Tang and Kern, 2011). However the role of the
complement system in DR pathogenesis is less well appreciated.
Early work by Gerl et al. (2002) demonstrated that chor-
iocapillaris of DR eyes contain signiﬁcant levels of C3d and the
C5b-9 complex. C5b-9 deposition was also detectable in retinal
vessels of patients with 49-year T2D (Zhang et al., 2002). In-
creased C5a was detected in the vitreous of patients with pro-
liferative DR (Muramatsu et al., 2013). Muller cells constitutively
express C5aR and the expression can be upregulated by hy-
perglycemia and inﬂammatory stimuli such as PGE2 (Cheng et al.,
2013). The ligation of C5aR with C5a in Muller cells results in the
release of IL-6 and VEGF (Cheng et al., 2013); both are known to be
critically involved in DR pathology. The results suggest that com-
plement activation is involved in retinal vascular damage in DR
(Nozaki et al., 2006).
How the complement system is activated in the diabetic eye is
not known. The expression of complement inhibitors CD55 and
CD59 was reduced in retinal vessels of DR eyes (Zhang et al., 2002).
Interestingly, C1q, C4 and MBL were not detected in the DR eyes
(Gerl et al., 2002; Zhang et al., 2002), indicating that the com-
plement system may be activated through the alternative pathway
in DR.
6.4. Complement activation in glaucoma
Primary glaucoma is an age-related chronic optic neuropathy
resulting from increased intraocular pressure (IOP). Glaucoma
causes progressive peripheral vision loss and, if untreated, may
lead to blindness. The most representative pathologic ﬁnding in
glaucoma is the death of retinal ganglion cells by apoptosis.
Current treatment for glaucoma is aimed at reducing IOP using
medicinal or surgical approaches. However a signiﬁcant number of
patients continue to lose vision after IOP is controlled. Compelling
evidence suggests that inﬂammation, including complement ac-
tivation contributes to ganglion cell death in glaucoma. Tezel et al.
(2010) reported the upregulation of various complement compo-
nents (predominately involved in CP) and down-regulation of
complement inhibitors in glaucoma retinae using proteomic ana-
lysis. Using microarray techniques, Howell et al. (2011) showed
that the complement cascade was upregulated at the early stages
of glaucoma in DBA/2J mice. In the experimental model of glau-
coma, C5b-9 deposition was detected at the ganglion cell layer and
complement depletion reduced ganglion cell loss (Jha et al., 2011).
Furthermore, mice with C1qa or C5 (Howell et al., 2011; Howell
et al., 2013) deﬁciency were protected from glaucoma. These re-
sults suggest that complement activation through the classical
pathway may contribute to retinal ganglion cell death in
glaucoma.7. Targeting the complement system for the management of
retinal disease
Despite convincing evidence that complement activation con-
tributes to retinal pathology in the aforementioned sight-threa-
tening diseases, so far the clinical predictive or therapeutic value
of these ﬁndings has not materialized. When targeting the com-
plement system for therapy, it is important to evaluate the bene-
ﬁcial and detrimental aspects of complement activation in retinal
disease. On one hand, the generation of C3b is beneﬁcial for
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moting phagocytosis of dead cells and debris). On the other hand,
MAC-mediated cell death or C3a/C5a induced immune activation
may contribute to retinal pathology. Ideally the therapy should be
sufﬁcient to constrain exacerbated complement activation without
shutting down necessary biological functions pertinent to immune
surveillance or tissue homeostasis. Complement activation in-
volves a cascade of multiple steps, and each step might be targeted
for therapy. The chosen therapy should consider the pathologic
mechanisms of the disease such as the triggers of complement
activation, the pathways, the location, and the disease course.
7.1. General principles for developing complement-targeted drugs
Avoiding toxicity: The complement system has many essential
physiological roles in retinal defences. Therefore, any comple-
ment-targeted therapy should cause as little disruption of its
physiological roles as possible, particularly if the treatment is to be
continued in the long-term. The strategies to reduce the adverse
effects related to complement inhibition may include: (1) target-
ing down-stream of the complement pathway, i.e., MAC formation,
for which the only risk is infection; (2) transient inhibition of
complement activation (may only be applicable for acute dis-
eases); (3) targeting complement activation locally in the retina.
This should be the preferred approach to manage retinal diseases
that are caused predominately by local variants, such as glaucoma
and AMD. However, both glaucoma and AMD are chronic diseases,
and may require long-term (years) management. The toxicity of
long-term complement inhibition in the retina should be carefully
considered. In DR and uveoretinitis the ocular barrier is often
disrupted and systemic immune alteration contributes sig-
niﬁcantly to retinal pathogenesis. Although control of local im-
mune activation, including complement activation is important for
preserving retinal structure and function, rectifying the systemic
immune response should also be considered, particularly at the
acute stage of the disease.
Selecting targets for complement inhibition: How to control the
complement system for the management of retinal diseases is an
important and but often difﬁcult question. With various potential
sites of inhibition to be considered, the knowledge of how the
complement system is activated and which pathways are involved
will be essential to identify the target of inhibition. In general, the
targets that can be considered for therapy may include the in-
itiators, regulators, and ampliﬁcation of the cascade, and the ef-
fectors of the complement system. The initiators include comple-
ment components that form the activation complex (e.g., C1q in
the CP, C3 in the AP, and MBL in the lectin pathway) and relevant
enzymes (C1r and C1s in the CP, MASP1 and MASP2 in the lectin
pathway, and C3 convertases in the AP). The regulators include
membrane-bound molecules (SIGNR, CR1-4, CRIg, CD46, CD55,
CD59) and soluble proteins (C4BP, C1INH, CFH, CFHR1, FHL1,
properdin, clusterin, vitronectin) that negatively regulate com-
plement activation (Zipfel and Skerka, 2009) as well as enzymes
involved in the ampliﬁcation stage (e.g., factor D). The effectors
include C5b-9 (MAC) and the anaphylactic proteins C3a and C5a.
The targeting approaches may include neutralizing antibodies
against the assembling compounds, enzymes or the synthetics of
the inhibitors. There are a number of complement inhibitors that
selectively target each of the above points that have been ap-
proved by the United States Food and Drug Administration (FDA)
or the European Medicines Agency (EMA) in clinical development
and others are in pre-clinical development for inﬂammatory dis-
eases such as hemolytic uremic syndrome, ischemia-reperfusion
injury, organ transplant rejection, and thrombotic microangio-
pathy (Reis et al., 2015) (Table 1).
In different retinal diseases the complement systemcontributes differently to the pathogenesis. Therefore, treatment
strategies should differ depending on disease pathogenesis. In
uveoretinitis, for example, the effectors (MAC, C5a) are known to
play a key role in retinal damage, and a previous study has shown
that targeting C5 (local or systemic) could effectively suppress
experimental autoimmune uveoretinitis (Copland et al., 2010).
Regrettably, little is known about how the complement system
damages the retina in other disease conditions including AMD
despite many years of intensive study. That is reﬂected by the poor
outcomes in complement based clinical trials (see below).
7.2. Current progress in complement based therapy for retinal
diseases
There are a number of complement-targeting drugs in clinical
(Table 2) and pre-clinical trials for retinal diseases, predominately
for the management of AMD with only one trial for non-infections
uveitis patients (NCT01526889, Table 2), and two trials for optic
neuritis (NCT02003144, NCT01759602, Table 2).
7.2.1. Non-infectious Uveitis
LFG316 is a C5-speciﬁc mAb developed by Novartis. It is in
phase 2 clinical trials for a number of complement related dis-
eases, including Paroxysmal nocturnal hemoglobinuria (PNH),
AMD, and non-infectious uveitis. In the uveitis study
(NCT01526889), LFG316 will be administered intravitreally (IVT) to
patients with active, non-infectious intermediate-, posterior-, or
panuveitis, and the safety, efﬁcacy and pharmacokinetics will be
assessed over a 12-week period. The trial is ongoing.
7.2.2. AMD
There are a number complement inhibitors are in phase 1-3
clinical trials for the treatment of AMD (Table 2), including one
inhibitor (POT-4) targeting C3, four (LFG316, Eculizumab, Zimura,
and ARC1905) targeting C5, and another one targeting factor D
(Lampalizumab formerly FCFD4514S). The majority of the trials
have shown a good record of safety, however the efﬁcacy remains
to be determined.
C3-targeted inhibitor: POT-4/Compostatin is a cyclic peptide
that inhibits C3 cleavage and prevents complement activation. An
in vitro study has shown that compostatin could inhibit drusen-
like deposits in human RPE cultures (Gorham et al., 2013). Fur-
thermore, an in vivo study in a monkey model of early-onset
macular degeneration observed the disappearance of drusen
6 months after intravitreal injection of compostatin (Chi et al.,
2010). A phase 1 study to evaluate the safety and tolerability of
intravitreal POT-4 injection for treatment of patients with neo-
vascular AMD was conducted between 2007 and 2010
(NCT00473928). However, positive results, if any, have never been
reported.
C5-targeted inhibitors: LFG316 is a fully-human, high-afﬁnity
antibody against C5 and can prevent C5 cleavage. The phase
2 studies of LFG316 for both GA (NCT01527500) and neovascular
AMD (NCT01535950) were completed in 2015, and the results are
yet to be reported.
Eculizumab, another C5 speciﬁc mAb, had been approved for
the treatment of PNH and atypical hemolytic uremic syndrome
(aHUS) (Rother et al., 2007). A phase 2 study has shown that up to
24 weeks intravenous infusions of Eculizumab was well-tolerated
by AMD patients through 52 weeks follow-up (Yehoshua et al.,
2014). However, neither GA progression (Yehoshua et al., 2014) nor
drusen volume (Garcia Filho et al., 2014) was affected by the
therapy despite signiﬁcant reduction on circulating C5 activity (to
less than 9% of normal levels by week one and less than 1% by
week two after treatment) (Yehoshua et al., 2014). The results
suggest that systemic complement activation may have limited
Table 1
Complement inhibitors that have been approved or are in preclinical or clinical studies.
Target point Compounds Mechanism of inhibition Company Application and Status
Initiators Berinert Plasma-derived human C1-INH CSL Behring Approved for hereditary angioedema (HAE)
Ruconest C1 esterase inhibitor (recombinant) Pharming Group N.V. Approved for HAE
Cinryze Plasma-derived human C1-INH ViroPharma Biologics Approved for HAE
TNT009 C1 s inhibitor (mAb) True North Therapeutics Phase 1
OMS721 MASP-2 antibody Omeros Corporation Thrombotic microangiopathies, phase 2
Regulators or ampliﬁcation
cascades
Lampalizumab Factor D mAb fragment Genentech Phase 3 trials for AMD
APL-1/2 C3 (Compstatin derivatives) Apellis Pharmaceuticals Phase 1 for Paroxysmal nocturnal hemoglobinuria (PNH)
AMY-101 C3 (Compstatin derivatives) Amyndas Pharmaceuticals Pre-clinical study in PNH
TP10 Soluble CR1 Celldex Phase 1 for patients with C3 glomerulopathy
Phase 2 for adult women undergoing cardiopulmonary bypass surgery
TT30 Fusion protein linking CR2 and CFH Alexion Pharmaceuticals Phase 2 or PNH
Mini-FH Engineered version of CFH Amyndas Pharmaceuticals Pre-clinical study in C3 glomerulopathy
Effectors Mubodina/Ergidina C5 speciﬁc mAb Adienne S.A. Pre-clinical study in aHUS
Eculizumab C5 speciﬁc mAb Alexion Pharmaceuticals Approved for PNH and aHUS; Phase 1–2trials for neuromyelitis optica, kidney graft reperfusion
injury, AMD, myasthenia gravis, Guillain-Barre syndrome, etc.
Zimura, ARC1905 Both are synthesized C5 inhibitors
(aptamer)
Ophthotech Phase 2 for AMD
LFG316 C5 speciﬁc mAb Novartis Phase 2 for AMD, PNH and non-infectious uveitis
Coversin Recombinant small protein (prevents
C5 cleavage)
AKARI Therapeutics Phase 2 for PNH
ALN–CC5 C5 speciﬁc RNAi Alnylam Phase 1 and 2 for PNH
CaCP29 C5a speciﬁc mAb InﬂaRx Phase 2 for septic organ dysfunction
CCX168 C5aR inhibitor ChemoCentryx Phase 2 for aHUS, ANCA-associated vasculitis, and IgA nephropathy
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H. Xu, M. Chen / European Journal of Pharmacology 787 (2016) 94–104 101effect on AMD pathology. Further study on the effect of intravitreal
administration of Eculizumab in AMD has not been reported.
Zimuras and ARC1905 are aptamer C5 inhibitors developed by
the Ophthotech Corporation. Zimuras is in phase 2 trials as a
combined therapy with anti-VEGF for the management of neo-
vascular AMD (NCT02397954), whereas ARC1905 is being tested
for both GA (NCT00950638) and nAMD (NCT00709527).
CFD-targeted inhibitor: Factor D (CFD) is responsible for
cleaving factor B, an essential substrate for the formation of C3
convertase (C3bBbC3b) of the AP. Targeting CFD can effectively
suppress AP-mediated complement activation. Lampalizumab
(FCFD4514S) is a humanized IgG Fab fragment directed against
CFD. Intravitreal injection of lampalizumab in cynomolgus mon-
keys at high doses (410 mg) resulted in transient (0.5–3 h) in-
hibition of systemic AP activity (Loyet et al., 2014). The results
from phase 1–2 studies were published on June 11, 2015 in Clinical
Ophthalmology (Rhoades et al., 2015). However, the paper was
retracted two weeks later (June 26, 2015) because “the results
referenced in this manuscript are preliminary analyses and may
not reﬂect the ﬁnal data and conclusions of the clinical trials ci-
ted”. Nevertheless, the paper reported that (1) a phase 1 study
showed that intravitreal injection of lampalizumab (up to 10 mg)
was well-tolerated through 90 days by GA patients; (2) a phase
2 study (MAHALO) showed that the size of GA reduced by 20.4%
from baseline after 18 months treatment. Further subgroup ana-
lysis revealed a 44% reduction in patients who were positive for
exploratory biomarkers (i.e., mutations for CFH, C3, or C2/CFB)
(Po0.005) (Rhoades et al., 2015). These results were originally
reported by Holz et al at the 14th EURETINA Congress in 2014
(http://www.euretina.org/london2014/programme/free-papers-de
tails.asp?id=3439&day=0). Phase 3 clinical trials to evaluate the
efﬁcacy and safety of intravitreal injection of lampalizumab for the
treatment of GA are ongoing (Table 2) (PharmaTimes).
Despite millions of dollars having been spent and nearly a
decade of intense research, the results so far from the clinical trials
have produced disappointing primary outcomes (i.e., minimal
improvement in visual acuity or reduction in disease progression)
(Table 2). Most of these trials have ended early as a result of dis-
appointing interim results and others with no reason reported
(with only one exception, Table 2). The disappointing results from
clinical trials have highlighted our lack of basic understanding
about the mechanisms by which complement factors inﬂuence
AMD development (Reynolds et al., 2009, Scholl et al., 2008). Thus
we are unable to address precisely when, where, and how to in-
hibit complement activation in different types of AMD.
Since AMD has strong genetic predisposition, it has been pro-
posed that genetic screening may help to predict treatment re-
sponsiveness. Indeed the MAHALO study, although preliminary,
has observed better responses to Lampalizumab from GA patients
with complement gene mutations (Rhoades et al., 2015). However,
the data about whether polymorphisms in complement genes and
other AMD risk factor genes can be used to predict the response to
VEGFA‑targeted therapies are conﬂicting (Hagstrom et al., 2013,
Smailhodzic et al., 2012). Similarly, genetic models fail to predict
progression to geographic atrophy (Klein et al., 2010, Scholl et al.,
2009). We have shown recently that the level of complement ac-
tivation differs in different types of AMD (Lechner et al., 2016).
A complex approach, taking into account genetic information,
environmental risk factors, biological phenotypes and clinical
presentation, may be a more appropriate way forward in devel-
oping complement based personalized therapy for AMD and other
retinal diseases.
8. Future perspectives and conclusions
The discovery of the link between complement gene
H. Xu, M. Chen / European Journal of Pharmacology 787 (2016) 94–104102polymorphisms and AMD risk has prompted a resurgence in in-
vestigating the role of the complement system in retinal diseases.
As a result, our knowledge of this topic has advanced considerably
in the past decade, which has prompted the design of distinct
strategies to develop complement based therapies for AMD pa-
tients. There are a few FDA approved complement inhibitors for
other inﬂammatory diseases, and clinical experience from these
studies suggests that complement-targeted therapies can be safe
and effective. In addition, there are over 40 ongoing clinical trials
evaluating different classes of complement inhibitors in numerous
diseases. These clinical studies will provide valuable information
about the safety and efﬁcacy of distinct strategies for complement
targeting, which offers a great opportunity to develop comple-
ment-based therapies for sight-threatening retinal diseases. For
each retinal disease, future research should address how the
complement system is activated, which complement pathway is
involved, which complement components cause retinal pathology
and at which stage of the disease, and whether the complement
system affects the eye systemically or locally. This knowledge will
be important in deciding whether complement inhibition should
be applied systemically or locally to treat disease, and when and
how the complement system should be targeted for therapy. As
complement activation is not the initial cause of the disease, it is
understandable that complement inhibition on its own may not be
sufﬁcient to control retinal pathology, and concomitant targeting
of disease aetiology may maximize the beneﬁts.Disclosures
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